The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 28, 2018

Filed:

Dec. 06, 2016
Applicant:

Millendo Therapeutics, Inc., Ann Arbor, MI (US);

Inventors:

Stephen Warren Hunt, III, Dexter, MI (US);

Martin Douglas Phillips, Bryn Mawr, PA (US);

Robert Matunas, East Windsor, NJ (US);

Herman Chen, Madison, CT (US);

Aimesther Betancourt, Montréal, CA;

Charles Uzarama, Laval, CA;

Roch Thibert, Ville Mont-Royal, CA;

Assignee:

Millendo Therapeutics, Inc, Ann Arbor, MI (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/50 (2006.01); C07C 275/28 (2006.01); C07C 273/18 (2006.01); A61K 9/20 (2006.01); A61K 31/17 (2006.01);
U.S. Cl.
CPC ...
C07C 275/28 (2013.01); A61K 9/2018 (2013.01); A61K 9/2054 (2013.01); A61K 9/2059 (2013.01); A61K 9/2081 (2013.01); A61K 9/5084 (2013.01); A61K 31/17 (2013.01); C07C 273/1809 (2013.01); C07C 2601/08 (2017.05);
Abstract

A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N'-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to 'ATR-101') suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome.


Find Patent Forward Citations

Loading…